Novo Nordisk’s amycretin is a single molecule designed to bind to two targets to spark weight loss — a different approach than some of the pharma giant’s other efforts to develop next-generation obesity drugs. Analysts say the lack of details safety and tolerability details make it difficult to fully assess the preliminary Phase 1b/2a results.
The post Novo Nordisk Obesity Drug Shows 22% Weight Loss, But Lack of Safety Detail Is a Sticking Point appeared first on MedCity News.
